Preclinical Imaging Market Size, COVID-19 Impact Analysis, Regional Outlook, Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027
Report ID: GMI1881
Preclinical Imaging (In-VIVO) Market Size will be strong over 2021-2027, in terms of value and volume. An upsurge in the demand for non-invasive small animal imaging techniques and developments in molecular imaging will foster the market growth.
Preclinical imaging (In-VIVO) has come up as an essential tool to boost biomedical discovery. It is used in live animal research for drug development and to monitor the treatment response. It is mainly used in compound optimization, target identification and observe changes in cell, tissue organs. In vivo plays a pivotal role in drug discovery, phenotyping and offers a basic assessment of mechanisms of disease.
In terms of modality, market value from the micro-ultrasound systems segment will expand at a robust CAGR through 2027. Micro-ultrasound imaging modality has become highly sought-after in research activities about small animal models. It will help predict the outcome of new treatments in patients and will help assess physiological, cellular, and molecular changes in living animals. Stakeholders are expected to invest in micro-ultrasound imaging modality for assessing morphology, placental, and fetal haemodynamic. Additionally, micro-ultrasound imaging will fuel further developments in urological imaging.
The PET segment will witness an appreciable gain by 2027 following its popularity to analyze an efficacy of therapeutic interventions. Preclinical PET also plays a pivotal role in validating the uses of both novel and current radiotracers for translation to humans. It provides 4D dynamic imaging, while image acquisition parameters can be tailored to visualize tracer distribution.
Based on end-user, the research organization segment is likely to account for a considerable share by 2027. For instance, Single Photon Emission Computed Tomography (SPECT) imaging has become popular as a versatile imaging technique with potentials in drug development and biomedical research. Besides, image modalities have become paramount for researchers to observe changes. Notably, modalities that are in vivo are sought to study animal models longitudinally. It is predicted that the combination of micro-CT with micro-PET will expand the horizon of research in neurology, oncology, cardiology, and epidemiology.
In terms of region, North America preclinical imaging market revenue will grow at a sizable rate during the forecast period 2021-2027. A slew of factors such as robust adoption of novel molecular imaging technologies, R&D activities for life science researchers and a considerable presence of pharmaceutical and biotechnological companies reinforces the lucrative opportunities in the U.S. Moreover, an increase in the number of preclinical projects has encouraged leading companies to augment investments across the region.
Key vendors in the global market are IDEX Health & Science, GE Healthcare, Berthold Technologies, UVP, Siemens Healthcare, Bruker Biospin, Visage Imaging, Koninklijke Philips and Nikon, among others. The competitive scenario suggests increased focus on R&D activities, innovations, and mergers & acquisitions.
GE Healthcare, for instance, acquired Zionexa in May 2021 to ramp up the latter’s FDA-approved PET imaging agent to help inform treatment selection for patients with metastatic or recurrent breast cancer. They will drive innovations in in-vivo oncology and neurology biomarkers and enable personalized healthcare solutions.
Preclinical imaging market response to COVID-19
The COVID-19 pandemic has imposed a scenario never seen before where norms and guidelines of treatment are challenged by strain on healthcare resources. The preclinical imaging research and development observed a steep plunge in the first and second quarter of 2020 due to an increased shortage of raw materials and shutdown of manufacturing units. However, the industry outlook is poised to gain prominence in post-COVID environments.
Industry participants are likely to shift their focus towards technological advancements and research in oncology. Modalities such as PET and SPECT imaging will remain instrumental in drug development and biomedical research.
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability